SGA
RPRX icon

Seaport Global Advisors’s Royalty Pharma RPRX Stock Holding History

Seaport Global Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2,651
Closed -$71.9K – 92
2023
Q3 		$71.9K Buy
+2,651
New +$78.7K 0.22% 85

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Seaport Global Advisors's RPRX Position: Q4 2023 in Review

Seaport Global Advisors sold out of Royalty Pharma (RPRX) in Q4 2023, closing a stake of 2,651 shares — an estimated $71.9K sold.

Seaport Global Advisors first reported a position in RPRX in Q3 2023 and held it in 1 quarter. The position peaked at $71.9K in Q3 2023. 363 funds tracked by Wall St. Rank hold RPRX as of Q4 2023.

  • Seaport Global Advisors reported no remaining Royalty Pharma position as of Q4 2023 after selling out during the quarter.
  • Seaport Global Advisors sold 2,651 Royalty Pharma shares in Q4 2023, an estimated $71.9K.
  • Seaport Global Advisors first reported a position in Royalty Pharma in Q3 2023 and held it in 1 quarter.
  • Seaport Global Advisors's Royalty Pharma position peaked at $71.9K in Q3 2023.
  • 363 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2023.

Based on Seaport Global Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.